MASLD and MASH Drug Review

This 2026 paper is a structured narrative review, not a treatment trial. It enrolled no participants and produced no new efficacy estimate. The author maps medicines for metabolic dysfunction-associated steatotic liver disease and steatohepatitis, abbreviated MASLD and MASH, by regulatory status and strength of evidence. Approved treatment for selected patients is separated from promising but investigational candidates^[1].

The distinction is important for tirzepatide. The review lists it among therapies that may broaden future treatment, not among the two medicines it describes as anchoring approved MASH-directed care. Readers can use our tirzepatide evidence overview for the wider research record without treating a liver-disease review as a personal treatment recommendation.

The review organized a fast-changing field

The author searched PubMed and ClinicalTrials.gov through September 2026 without a lower date limit. Regulatory documents from the United States and Europe supplemented the search, along with society guidance. The synthesis also considered randomized trials and evidence reviews, plus selected mechanistic studies^[2]. The abstract calls this a structured narrative review rather than a systematic review or meta-analysis.

That design can explain how treatment classes fit together and where evidence gaps remain. It cannot pool results into one effect size or directly rank medicines, and it cannot remove differences among trial populations. Cross-trial comparisons are especially difficult when studies use different disease stages and follow-up periods. Surrogate endpoints add another difference because they use laboratory or tissue measures in place of later clinical outcomes.

The review evaluates therapies according to mechanism and regulatory status. It considers endpoint strength alongside safety. Drug interactions and implementation also enter the framework^[1]. This reflects the clinical reality that liver disease often occurs alongside obesity or type 2 diabetes. Cardiovascular risk and kidney disease may also shape treatment decisions, as can abnormal lipids. Those overlapping conditions can change which outcome matters most to an individual patient.

Two approved therapies anchor the review

The abstract states that resmetirom and semaglutide anchor approved MASH-directed treatment for eligible adults with noncirrhotic disease and F2 to F3 fibrosis^[2]. F2 and F3 refer to clinically meaningful stages of liver fibrosis, or scarring, before cirrhosis. Eligibility remains narrower than simply having fatty liver, obesity, or an abnormal liver test.

Approval does not make the two medicines interchangeable. They act through different mechanisms and may fit different clinical priorities. The review's framework asks clinicians to consider liver stage alongside cardiometabolic needs. It does not provide a universal sequence or claim that every person with MASLD needs a MASH-directed medicine.

The paper also discusses comorbidity-directed therapy. A medicine used for diabetes, weight management, lipid control, cardiovascular risk, or kidney disease can be relevant to the whole patient even when it is not approved as a direct MASH therapy. That category should not be confused with a disease-specific liver indication.

Tirzepatide remains an emerging candidate

In the expert-opinion section, the author names tirzepatide alongside FGF21 analogues and denifanstat as candidates that may broaden treatment. Rational combinations are another research direction^[1]. The wording is prospective. It does not say that tirzepatide has an approved MASH indication or that its trial results can be compared directly with approved medicines.

Tirzepatide targets GIP and GLP-1 receptors, linking it to the review's incretin category. Changes in weight and metabolic health can accompany changes in liver fat or tissue endpoints, but a surrogate response does not automatically establish fewer liver complications. A candidate therapy still needs trials designed for the relevant liver population and outcomes.

The review also covers glucagon-containing agonists, thyroid hormone receptor-beta agonism, and FGF21 analogues. Other sections address metabolic pathways involved in lipid handling or glucose transport. Listing a mechanism indicates scientific interest, not equal evidence across categories. Some candidates remain supported mainly by earlier or lower-strength data.

Surrogate endpoints limit comparisons

The author explicitly cautions against cross-trial comparisons and overreading surrogate endpoints^[2]. Trials may assess resolution of steatohepatitis, improvement in fibrosis, imaging changes, or biomarkers. These measures answer different questions, and improvement in one does not guarantee improvement in another.

Differences in baseline fibrosis also matter. A result in noncirrhotic F2 or F3 disease cannot be assumed to apply to early steatosis or established cirrhosis. Safety and interactions may shift with liver function, other illnesses, and concurrent medicines. The review's broad map is useful for orientation, but it cannot replace the eligibility rules and monitoring used in clinical care.

What the review cannot decide

The article does not establish a best medicine for MASLD or MASH. It does not test a treatment sequence, compare tirzepatide head to head with resmetirom or semaglutide, or determine whether combining agents improves patient outcomes. As a narrative synthesis, it also cannot supply a single estimate of benefit or harm across a varied literature.

The practical conclusion is limited. Treatment must match confirmed liver stage and the person's wider health priorities. People should not infer eligibility from a review abstract or change a prescribed metabolic medicine to target liver disease. Assessment by a qualified clinician may involve laboratory testing, imaging, or fibrosis evaluation before the treatment discussion begins.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.